VTN and prostate carcinoma: To validate the use of FN1 and VTN as prognostic biomarkers for prostate cancer, we used the newly established ELISAs to analyze samples from 118 patients from the Hamburg prostatectomy cohort of patients who had been treated with prostatectomy and for who long-term biochemical recurrence-free survival data are available (Table 1A).